As biotechnology issues erupt inside the Beltway and beyond, the trade association known as BIO is increasingly under the microscope.

The controversy surrounding the development of the human DNA map, congressional inquiries into gene therapy experiments, and the regulatory and marketplace skirmishes over genetically modified foods has spurred business for the Biotechnology Industry Organization. A seven-year-old association, BIO has grown four-fold in the last few years and taken the lead on behalf of one of the economy’s most dynamic new forces.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]